Reports
Sale
North America Anti-Obesity Drugs Market Size, Share, Growth: By Drugs: Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Others; By Drug Class; By Mechanism of Action; By Route of Administration; By Prescription Type; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
North America Anti-Obesity Drugs Market Outlook
The North America anti-obesity drugs market size is expected to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity and the growing demand for effective anti-obesity drugs with fewer side effects in the region.
Key Takeaways
- In the United States, 41.9% of adults are estimated to be obese. The rising prevalence of obesity directly impacts the demand for effective and affordable anti-obesity drugs.
- In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. The market is witnessing a surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA), which is expected to boost the North America anti-obesity drugs market share in the forecast period.
- In August 2023, Novo Nordisk A/S planned to acquire a Canada-based biotechnology company Inversago Pharma in a deal worth over USD 1 billion to expand its obesity and diabetes portfolio. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative anti-obesity drugs.
North America Anti-Obesity Drugs Market Analysis
Anti-obesity drugs are expected to aid in weight management with minimal side effects by inducing fat absorption, appetite suppression, and metabolic enhancement, among others. In North America, there is a rising acceptance of obesity as a chronic disease requiring medical intervention rather than just lifestyle changes. This shift in perception coupled with heightened patient awareness and the presence of advanced healthcare infrastructure in the region is expected to contribute to the North America anti-obesity drugs market growth.
Recent data suggests that obesity rates in North America are sharply increasing. In the United States, 41.9% of adults are estimated to be obese, out of which, Black and Latino populations have the highest rates of obesity at 49.9% and 45.6%, respectively. The rising prevalence of obesity impacts the demand for effective and affordable anti-obesity therapeutics significantly. Furthermore, the increased focus on research in obesity management to combat the growing cases in the region is anticipated to boost market size in coming years.
One of the significant North America anti-obesity drugs market trends is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Eli Lilly and Company manufactured Zepbound (containing the active ingredient tirzepatide). It is designed for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication. Zepbound is known to activate certain hormone receptors in the intestine that reduce food intake and suppress appetite. Its efficacy was evaluated in two randomized controlled trials which showed that Zepbound can result in a statistically significant reduction in body weight. The increased availability of such effective anti-obesity drugs is likely to elevate market value.
The market is witnessing increased merger and acquisition initiatives from the key market players. Such strategic partnerships are expected to lead to accelerated development and commercial availability of innovative therapeutics, thereby fuelling North America anti-obesity drugs market demand. In September 2023, Novo Nordisk A/S acquired a Canada-based biotechnology company, called Inversago Pharma in a deal worth over USD 1 billion. The partnership was intended to expand its obesity and diabetes portfolio. The company also aims to assess the potential of Inversago’s lead candidate, INV-202, which is known to block the CB1 receptor involved in the regulation of appetite and metabolism, in obesity and associated complications. Such substantial investments in the anti-obesity drug pipelines are expected to improve access to obesity treatments, which will positively impact the market share.
North America Anti-Obesity Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Drugs | Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, Tirzepatide |
| Drug Class | Amphetamine, GLP-1 receptor agonist, Lipase Inhibitor |
| Mechanism of Action | Centrally Acting Drugs, Peripherally Acting Drugs |
| Route of Administration | Oral, Subcutaneous |
| Prescription Type | Prescription Drugs, Over the Counter Drugs |
| Distribution Channel | Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies |
| Countries | United States of America, Canada |
North America Anti-Obesity Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- Gelesis Holdings Inc. (PureTech Health)
- Currax Pharmaceutical LLC (Currax Holdings USA LLC)
- Vivus LLC
- Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH)
- KVK Tech, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Route of Administration |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Anti-Obesity Drugs Market Overview
3.1 North America Anti-Obesity Drugs Market Historical Value (2017-2023)
3.2 North America Anti-Obesity Drugs Market Forecast Value (2024-2032)
4 North America Anti-Obesity Drugs Market Landscape*
4.1 North America Anti-Obesity Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Anti-Obesity Drugs Market: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Product Type
5 North America Anti-Obesity Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Anti-Obesity Drugs Market Segmentation (2017-2032)
6.1 North America Anti-Obesity Drugs Market (2017-2032) by Drugs
6.1.1 Market Overview
6.1.2 Semaglutide
6.1.3 Phentermine/Topiramate
6.1.4 Naltrexone/Bupropion
6.1.5 Liraglutide
6.1.6 Gelesis 100
6.1.7 Orlistat
6.1.8 Phentermine
6.1.9 Methamphetamine
6.1.10 Tirzepatide
6.2 North America Anti-Obesity Drugs Market (2017-2032) by Drug Class
6.2.1 Market Overview
6.2.2 Amphetamine
6.2.3 GLP-1 receptor agonist
6.2.4 Lipase Inhibitor
6.3 North America Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
6.3.1 Market Overview
6.3.2 Centrally Acting Drugs
6.3.3 Peripherally Acting Drugs
6.4 North America Anti-Obesity Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Subcutaneous
6.5 North America Anti-Obesity Drugs Market (2017-2032) by Prescription Type
6.5.1 Market Overview
6.5.2 Prescription Drugs
6.5.3 Over The Counter Drugs
6.6 North America Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Drug Store & Retail Pharmacies
6.6.4 Online Pharmacies
6.7 North America Anti-Obesity Drugs Market (2017-2032) by Countries
6.7.1 Market Overview
6.7.2 United States of America
6.7.3 Canada
7 United States of America Anti-Obesity Drugs Market (2017-2032)
7.1 United States of America Anti-Obesity Drugs Market (2017-2032) by Drugs
7.1.1 Market Overview
7.1.2 Semaglutide
7.1.3 Phentermine/Topiramate
7.1.4 Naltrexone/Bupropion
7.1.5 Liraglutide
7.1.6 Gelesis 100
7.1.7 Orlistat
7.1.8 Phentermine
7.1.9 Methamphetamine
7.1.10 Tirzepatide
7.2 United States of America Anti-Obesity Drugs Market (2017-2032) by Drug Class
7.2.1 Market Overview
7.2.2 Amphetamine
7.2.3 GLP-1 receptor agonist
7.2.4 Lipase Inhibitor
7.3 United States of America Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
7.3.1 Market Overview
7.3.2 Centrally Acting Drugs
7.3.3 Peripherally Acting Drugs
7.4 United States of America Anti-Obesity Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Subcutaneous
7.5 United States of America Anti-Obesity Drugs Market (2017-2032) by Prescription Type
7.5.1 Market Overview
7.5.2 Prescription Drugs
7.5.3 Over The Counter Drugs
7.6 United States of America Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
7.6.1 Market Overview
7.6.2 Hospital Pharmacies
7.6.3 Drug Store & Retail Pharmacies
7.6.4 Online Pharmacies
8 Canada A nti-Obesity Drugs Market (2017-2032)
8.1 Canada Anti-Obesity Drugs Market (2017-2032) by Drugs
8.1.1 Market Overview
8.1.2 Semaglutide
8.1.3 Phentermine/Topiramate
8.1.4 Naltrexone/Bupropion
8.1.5 Liraglutide
8.1.6 Gelesis 100
8.1.7 Orlistat
8.1.8 Phentermine
8.1.9 Methamphetamine
8.1.10 Tirzepatide
8.2 Canada Anti-Obesity Drugs Market (2017-2032) by Drug Class
8.2.1 Market Overview
8.2.2 Amphetamine
8.2.3 GLP-1 receptor agonist
8.2.4 Lipase Inhibitor
8.3 Canada Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
8.3.1 Market Overview
8.3.2 Centrally Acting Drugs
8.3.3 Peripherally Acting Drugs
8.4 Canada Anti-Obesity Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Subcutaneous
8.5 Canada Anti-Obesity Drugs Market (2017-2032) by Prescription Type
8.5.1 Market Overview
8.5.2 Prescription Drugs
8.5.3 Over The Counter Drugs
8.6 Canada Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
8.6.1 Market Overview
8.6.2 Hospital Pharmacies
8.6.3 Drug Store & Retail Pharmacies
8.6.4 Online Pharmacies
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Pfizer, Inc.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Boehringer Ingelheim International GmbH
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 GlaxoSmithKline PLC
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Novo Nordisk A/S
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Rhythm Pharmaceuticals, Inc.
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Gelesis Holdings Inc. (PureTech Health)
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Currax Pharmaceutical LLC (Currax Holdings USA LLC)
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Vivus LLC
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH)
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 KVK Tech, Inc.
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 9.30% during the forecast period of 2024-2032, driven by the rising prevalence of obesity in the region.
The increasing awareness about the health risks associated with obesity and the rising disposable incomes in the region are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals by health agencies such as the United States Food and Drug Administration (FDA). In November 2023, the FDA approved Zepbound developed by Eli Lilly and Company for chronic weight management in obese individuals or overweight individuals having at least one weight-related complication.
Based on the drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide.
Drug classes available in the market include amphetamine, GLP-1 receptor agonists, and lipase inhibitors.
By mechanism of action, the market is divided into centrally acting drugs and peripherally acting drugs.
The market breakup by route of administration includes oral and subcutaneous.
Based on the prescription type, the market includes prescription drugs and over-the-counter drugs.
Distribution channels of the market include hospital pharmacies, drug store & retail pharmacies, and online pharmacies.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceutical LLC (Currax Holdings USA LLC), Vivus LLC, Cheplapharm Arzneimittel GmbH (Braun Beteiligungs GmbH), and KVK Tech, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER